Attendee search 

Defined Health advises senior management at Life Sciences clients on the value of compounds  and technology platforms in development, from pre-IND to indication prioritization and sequencing,, repurposing, reformulation, and life cycle management. Our scientifically trained consultants leverage the firm's 30 years of experience with evaluations that are grounded in the science, and informed by an unparalleled understanding of current and evolving clinical practices, development and regulatory issues, competitive commercial dynamics and pricing, reimbursement and market access practices. 

In addition to our core Opportunity Assessment business, we have a large Search & Evaluation practice, wherein we identify and assess relevant opportunities for therapeutic area expansion, as well as a Strategy practice that addresses broader corporate development initiatives -- therapeutic and disease area and market entry strategies.

Our clients include 13 of the top 20 pharmacos, 6 of the top 10 large cap biotechs, and scores of specialty pharma and pre-commercial biotech companies, as well as several royalty investors and two of the top private equity firms.  We are proud to have an 80% repeat and referral client base.

Find out more about Defined Health and view our recent presentations on topical and therapeutic area specific subjects at www.definedhealth.com.

Ipsen is a global specialty-driven pharmaceutical company with total sales exceeding €1.2 billion in 2013. Ipsen’s ambition is to become a leader in specialty healthcare solutions for targeted debilitating diseases. Its development strategy is supported by three franchises: neurology / Dysport®, endocrinology / Somatuline® and uro-oncology / Decapeptyl®. Moreover, the Group has an active policy of partnerships. R&D is focused on innovative and differentiated technological patient-driven platforms, peptides and toxins. In 2013, R&D expenditure totaled close to €260 million, representing more than 21% of Group sales. The Group has close to 4,600 employees worldwide. 

Ipsen’s shares are traded on segment A of Euronext Paris (stock code: IPN, ISIN code: FR0010259150) and eligible to the “Service de Règlement Différé” (“SRD”). The Group is part of the SBF 120 index. Ipsen has implemented a Sponsored Level I American Depositary Receipt (ADR) program, which trade on the over-the-counter market in the United States under the symbol IPSEY. For more information on Ipsen, visitwww.ipsen.com and www.ipsenus.com.

Dr. Ahmad’s clinical philosophy reflects the wisdom of the Greek physician Hippocrates: it is more important to know what person the disease has than what disease the person has.

Samoon Ahmad, MD

We are industry leaders in strategy and solutions

Triad knows you are looking to collect as much information as you can about your competitors.  One of our favorite Sun Tzu quotes is “If you know the enemy and know yourself, you need not fear the result of a hundred battles.”  This is particularly fitting for competitive intelligence.  In order to be as strategic as possible, we encourage our clients to take stock of their own potential. We then work with them to figure out what questions we really need to answer about their competition, to make a difference in their future planning.  When you ask a question, you should know what you will do with the answer.

Triad views our process as highly interactive. We want to communicate with you throughout the project, so that as intelligence is gathered, it can be processed and redirected. Key Intelligence Topics get revisited regularly to make sure we are asking the best questions to the most knowledgeable sources.

With a well-designed research plan, a diverse contact list, and highly skilled analysts, Triad will confidently present you with the most insightful intelligence attainable. Since the process includes mapping out your strategy early on, our reports can deliver concise and actionable findings to help you and your team put your brand on the right path forward.

• Alissa Pharma is a new biotechnology company focusing on radioimmunotherapy with novel targeted antibodies for hematology and solid tumors.
• Alissa Pharma has a patented platform technology for the development of bispecific monoclonal antibodies combined with radioisotopes to address unmet medical needs in hematology and oncology.
• Lead Product: Ferritarg: 90Y antiferritin polyclonal antibody is ready to enter into a phase III trial. Originally developed for relapsed and refractory Hodgkin lymphoma by two well-known US institutions (Johns Hopkins in Baltimore and MD Anderson in Houston), Ferritarg has already demonstrated safety and efficacy in Phase I/II clinical trials in more than 300 patients.
• Alissa Pharma has secured the worldwide rights for Ferritarg in all radiopharmaceutical indications and the preclinical dossier is completed.
• The market potential is in excess of $100 million in US alone in this indication based on an estimated cost per patient of $60,000. The Orphan Drug Status for Ferritarg, already obtained in both Europe and the US for the Hodgkin lymphoma indication, offers a fast track regulatory pathway for approval and provides market exclusivity for 10 and 7 years in Europe and in the US, respectively, from the approval date.
• AMB8LK: 90Y antiferritin chimerized monoclonal antibody is in preclinical development for the treatment of pancreatic cancer (pancreatic cancer cells overexpress ferritin). Preclinical data indicated that AMB8LK has a very high affinity and specificity for human ferritin. AMB8LK, radiolabelled with 90Y showed 98% stability over 7 days.AMB8LK has a broad and well-protected patent estate. The product is ready to commence clinical trials. AMB8LK can also be developed in hepatic cancer and neuroblastoma.
• Alissa Pharma has an experienced management team with a proven track record of obtaining product approvalsin both Europe and the US and generating several successful exits. In addition to time, effort, and ownership, the management team has funded all of the expenses since the inception of Alissa Pharma